Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats

    loading  Checking for direct PDF access through Ovid


Chemotherapy can cause serious neurotoxic side effects, such as painful peripheral neuropathies and disabling cognitive impairments. Four experiments examined whether Ibudilast, a clinically approved neuroimmune therapy, would reduce tactile allodynia and memory impairments caused by oxaliplatin in laboratory rats. Rats received an intraperitoneal injection of oxaliplatin (6 mg/kg i.p.) or vehicle and were assessed for tactile allodynia 3 or 5 days after injection, memory impairments in the novel object and novel location recognition tests 10–12 days after injection, and fear conditioning 14 days after injection. Ibudilast (7.5 mg/kg) or vehicle was administered prior to oxaliplatin (Experiments 1 and 3) or prior to behavioural testing (Experiments 2 and 4). Ibudilast treatment prior to oxaliplatin prevented the development of tactile allodynia and memory impairments. Ibudilast treatment prior to behavioural testing reduced oxaliplatin-induced tactile allodynia, memory impairments, and impaired renewal of fear conditioning. These results suggest that Ibudilast could be an effective treatment against oxaliplatin-induced neuropathies and cognitive impairments.

Related Topics

    loading  Loading Related Articles